Regeneron Pharmaceuticals (REGN) continues to be a top pick in gene therapy sector according to hedge funds. The company's stock has garnered significant attention from financial entities such as American Century Companies Inc., Handelsbanken Fonder AB, and Banco Santander S.A., amongst others. The valuation of
REGN stock continues to be evaluated following recent changes in its share price, yet there are two main reasons it's expected to outperform the market in the coming decade. Its drug
Dupixent, recently approved by the FDA for allergic fungal rhinosinusitis, has substantially contributed to the strong financial standing of the company. Furthermore, there's been significant buying and selling activity related to their shares by prominent investment groups such as Harvest Portfolios Group Inc., Erste Asset Management GmbH, and Stevens Capital Management LP. The U.S. FDA has accepted a priority review for
REGN's new Biologics License Application (BLA) for Garetosmab. Despite the company’s recent share price pullback, a bull-case theory emerges from its promising innovations. Lastly, the firm’s commitment to corporate social responsibility is not unnoticed with an investment of over $300 million in promoting STEM education.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 04 Sep 2025 07:00:00 GMT to Sat, 28 Feb 2026 13:11:06 GMT -
Rating 8
- Innovation 7
- Rumor -5
